<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abingdon Health Plc — News on 6ix</title>
<link>https://6ix.com/company/abingdon-health-plc</link>
<description>Latest news and press releases for Abingdon Health Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abingdon-health-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835de4978dffbe2df125151.webp</url>
<title>Abingdon Health Plc</title>
<link>https://6ix.com/company/abingdon-health-plc</link>
</image>
<item>
<title>Admission to trading on OTCQB in the US</title>
<link>https://6ix.com/company/abingdon-health-plc/news/admission-to-trading-on-otcqb-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/admission-to-trading-on-otcqb-in-the-us</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>Abingdon Health plc has announced the admission of its ordinary shares to trading on the OTCQB Venture Market in the United States under the ticker symbol ABDXF, effective today. This listing on the OTCQB is designed for development stage companies and, as a foreign private issuer, Abingdon Health will not face additional reporting obligations or incur significant extra costs due to its exemption under US Exchange Act Rule 12g3-2(b), provided it continues to make information available to US inve</description>
</item>
<item>
<title>EMI Share Option Scheme</title>
<link>https://6ix.com/company/abingdon-health-plc/news/emi-share-option-scheme-2</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/emi-share-option-scheme-2</guid>
<pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
<description>Abingdon Health plc has allocated 3,096,000 share options under its EMI share option scheme to UK-based staff employed for at least 12 months, representing 1.23% of total issued shares. Half of these options, 1,548,000, will be allocated in April 2026, with the remaining 1,548,000 to be allocated in April 2027, and all shares will be exercisable at nil cost three years post-allocation.
Disclaimer*</description>
</item>
<item>
<title>Trading to commence on the OTCQB in the US</title>
<link>https://6ix.com/company/abingdon-health-plc/news/trading-to-commence-on-the-otcqb-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/trading-to-commence-on-the-otcqb-in-the-us</guid>
<pubDate>Tue, 14 Apr 2026 06:00:00 GMT</pubDate>
<description>Abingdon Health plc will commence trading on the OTCQB Venture Market in the United States on April 21, 2026, under the ticker symbol ABDXF, while continuing to trade on AIM as ABDX. This expansion into the US market follows the second phase of a facility expansion at its Madison, Wisconsin site, which aims to provide manufacturing capabilities in both the USA and UK to offer customers geographic optionality and address supply chain uncertainties. The company anticipates this move will increase </description>
</item>
<item>
<title>£4.8m contracts awarded</title>
<link>https://6ix.com/company/abingdon-health-plc/news/pound48m-contracts-awarded</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/pound48m-contracts-awarded</guid>
<pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
<description>Abingdon Health plc has secured approximately £4.8 million in new contracts with a US-based customer for the development and scaled manufacturing of multiplex quantitative lateral flow assay systems. These agreements, spanning roughly 27 months, encompass full programme management, regulatory processes, and analytical and clinical performance services, leveraging Abingdon's integrated CDMO/CRO capabilities across its UK and US facilities. The contracts represent a significant validation of the c</description>
</item>
<item>
<title>Half-year Financial Report</title>
<link>https://6ix.com/company/abingdon-health-plc/news/half-year-financial-report-114</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/half-year-financial-report-114</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>Abingdon Health plc reported a 45% increase in total revenue to £4.5 million for the six months ended December 31, 2025, with reported revenue reaching £4.2 million. The company expects the second half of fiscal year 2026 to be profitable with positive operating cash flow, and maintains its full-year revenue guidance of £12.6 million. Despite an adjusted EBITDA loss of £1.7 million in the first half due to investment in growth, the company secured new contracts, including a $2.5 million deal ann</description>
</item>
<item>
<title>$2.5m Contract for clinical self-test development</title>
<link>https://6ix.com/company/abingdon-health-plc/news/dollar25m-contract-for-clinical-self-test-development</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/dollar25m-contract-for-clinical-self-test-development</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>Abingdon Health plc has secured a significant contract valued at approximately US$2.5 million for the development and regulatory submission of a clinical self-test, with the majority of revenue expected in the financial year ending June 30, 2027. This 18-month project will involve Abingdon Health providing end-to-end project management and technical support across feasibility, design, development, verification, and validation phases, leveraging their expertise in lateral flow test development an</description>
</item>
<item>
<title>Trading on the OTCQB Venture Market in the US</title>
<link>https://6ix.com/company/abingdon-health-plc/news/trading-on-the-otcqb-venture-market-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/trading-on-the-otcqb-venture-market-in-the-us</guid>
<pubDate>Tue, 10 Mar 2026 07:00:00 GMT</pubDate>
<description>Abingdon Health plc announced that its ordinary shares will commence trading on the OTCQB Venture Market in the United States under the ticker symbol "ABDXF" starting next month, aiming to increase liquidity and attract a broader investor base. This move coincides with the ongoing second phase of a facility expansion at its Madison, Wisconsin site, which began in September 2025 and was funded in October 2025, allowing for manufacturing in both the US and UK under consistent quality standards. Th</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/abingdon-health-plc/news/notice-of-results-204</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/notice-of-results-204</guid>
<pubDate>Thu, 05 Mar 2026 07:00:00 GMT</pubDate>
<description>Abingdon Health plc has announced that it will release its interim results for the six months ending 31 December 2025 on Tuesday, 17 March 2026, and will host an investor presentation on the same day at 11:00 GMT via the Investor Meet Company platform.
Disclaimer*</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/abingdon-health-plc/news/trading-update-311</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/trading-update-311</guid>
<pubDate>Thu, 15 Jan 2026 07:01:00 GMT</pubDate>
<description>Abingdon Health plc reported a significant 45% increase in first-half FY26 revenues, reaching £4.5 million, driven by substantial commercial contracts. The company's cash reserves grew to £3.6 million following a £3.2 million net fundraising in October 2025, intended to support US expansion and working capital. Despite a shift in revenue timing for a key customer, Abingdon Health maintains its full-year FY26 revenue guidance of £12.6 million and anticipates profitability and positive operating c</description>
</item>
<item>
<title>Appointment of NOMAD & Corporate Broker</title>
<link>https://6ix.com/company/abingdon-health-plc/news/appointment-of-nomad-and-corporate-broker</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/appointment-of-nomad-and-corporate-broker</guid>
<pubDate>Thu, 15 Jan 2026 07:00:00 GMT</pubDate>
<description>Abingdon Health plc has announced the immediate appointment of Cavendish Capital Markets Limited as its sole Corporate Broker and Nominated Adviser. This strategic move is intended to enhance the company's financial advisory and regulatory support structure.
Disclaimer*</description>
</item>
<item>
<title>Exercise of options and total voting rights</title>
<link>https://6ix.com/company/abingdon-health-plc/news/exercise-of-options-and-total-voting-rights-47</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/exercise-of-options-and-total-voting-rights-47</guid>
<pubDate>Mon, 29 Dec 2025 14:35:00 GMT</pubDate>
<description>Abingdon Health plc has announced the exercise of share options, resulting in the application for 5,208 new ordinary shares to be admitted to trading on AIM on December 30, 2025. Following this issuance, the company's total issued ordinary shares will be 251,077,850, with no shares held in treasury. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>European patent for AppDx® smartphone reader</title>
<link>https://6ix.com/company/abingdon-health-plc/news/european-patent-for-appdxr-smartphone-reader</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/european-patent-for-appdxr-smartphone-reader</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>Abingdon Health plc has announced the granting of a new European patent, EP4150565, for its AppDx® lateral flow smartphone reader, following recent patent grants in the USA and UK. This AppDx® technology is a software development kit that utilizes smartphone cameras and deep learning algorithms to read colorimetric lateral-flow tests, enabling qualitative and semi-quantitative results. The company views this as a valuable tool for its contract development and manufacturing customers, highlightin</description>
</item>
<item>
<title>Result of Annual General Meeting</title>
<link>https://6ix.com/company/abingdon-health-plc/news/result-of-annual-general-meeting-103</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/result-of-annual-general-meeting-103</guid>
<pubDate>Wed, 10 Dec 2025 13:47:00 GMT</pubDate>
<description>Abingdon Health plc announced that at its Annual General Meeting held on December 10, 2025, all resolutions were passed with overwhelming support, receiving over 99.7% of votes in favour, indicating strong shareholder confidence in the company's direction and management.
Disclaimer*</description>
</item>
<item>
<title>Vesting and Award of Options under LTIP</title>
<link>https://6ix.com/company/abingdon-health-plc/news/vesting-and-award-of-options-under-ltip</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/vesting-and-award-of-options-under-ltip</guid>
<pubDate>Thu, 04 Dec 2025 07:00:00 GMT</pubDate>
<description>Abingdon Health plc announced updates regarding its Long Term Incentive Plan (LTIP), with 16% of FY23 LTIPs vesting based on FY25 revenue and EBITDA targets, resulting in 512,800 options vested at a 7 pence exercise price, while 2,692,199 LTIP shares lapsed. Additionally, new nil-cost LTIPs totaling 3,361,000 shares have been awarded, vesting around October 2028, contingent on achieving FY28 revenue and EBITDA targets. The total outstanding LTIP share options, after accounting for lapsed FY23 op</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/abingdon-health-plc/news/holdings-in-company-652</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/holdings-in-company-652</guid>
<pubDate>Tue, 02 Dec 2025 15:08:00 GMT</pubDate>
<description>Abingdon Health plc has been notified of changes in major shareholdings following a recent Placing and Retail Offer. Chris Yates, CatenaLucis LLC, and Thornapple LLP have each reduced their holdings to below 3% of the company's issued share capital, with previous holdings reported at 3.7%, 3.7%, and 3.2% respectively. These changes are due to an event changing the breakdown of voting rights.
Disclaimer*</description>
</item>
<item>
<title>Notice of AGM & Publication of 2025 Annual Report</title>
<link>https://6ix.com/company/abingdon-health-plc/news/notice-of-agm-and-publication-of-2025-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/notice-of-agm-and-publication-of-2025-annual-report</guid>
<pubDate>Fri, 14 Nov 2025 14:00:00 GMT</pubDate>
<description>Abingdon Health plc has announced that its Annual General Meeting will be held on Wednesday, December 10, 2025, at 12:00 GMT, and the company has also published its 2025 Annual Report. Printed copies of both documents have been sent to shareholders who receive paper communications, and they will soon be available on the company's website.
Disclaimer*</description>
</item>
<item>
<title>Final Results</title>
<link>https://6ix.com/company/abingdon-health-plc/news/final-results-348</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/final-results-348</guid>
<pubDate>Tue, 11 Nov 2025 07:00:00 GMT</pubDate>
<description>Abingdon Health plc reported final results for the financial year ended 30 June 2025, with total revenue increasing by 40.0% to £8.6 million, driven by strong growth in contract development and manufacturing organisation (CDMO) activities and the acquisition of CS Lifesciences. The company secured several significant contracts, including a US$2 million deal for sexually transmitted disease tests and an £800,000 funding award for malaria diagnostic tests. Despite an adjusted EBITDA loss of £2.7 m</description>
</item>
<item>
<title>c.US$2m multiplex diagnostic test contract win</title>
<link>https://6ix.com/company/abingdon-health-plc/news/cusdollar2m-multiplex-diagnostic-test-contract-win</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/cusdollar2m-multiplex-diagnostic-test-contract-win</guid>
<pubDate>Mon, 10 Nov 2025 07:00:00 GMT</pubDate>
<description>Abingdon Health plc has secured a new contract with an estimated value of US$2 million for the development, scale-up, and technical transfer of a semi-quantitative, multiplex lateral flow test system. This Master Service Agreement with a US-based company is expected to span approximately 24 months and will be managed from the company's Madison, Wisconsin facilities, highlighting the strength of its contract development and manufacturing organisation (CDMO) offering and its expanded US manufactur</description>
</item>
<item>
<title>Launch of seaweed-based lateral flow housings</title>
<link>https://6ix.com/company/abingdon-health-plc/news/launch-of-seaweed-based-lateral-flow-housings</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/launch-of-seaweed-based-lateral-flow-housings</guid>
<pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
<description>Launch of seaweed-based lateral flow housings.</description>
</item>
<item>
<title>Result of Meeting and TVR</title>
<link>https://6ix.com/company/abingdon-health-plc/news/result-of-meeting-and-tvr</link>
<guid isPermaLink="true">https://6ix.com/company/abingdon-health-plc/news/result-of-meeting-and-tvr</guid>
<pubDate>Thu, 30 Oct 2025 09:43:00 GMT</pubDate>
<description>Abingdon Health PLC announced that all resolutions proposed at its General Meeting on October 30, 2025, were duly passed, satisfying a condition for completion of its Fundraising. Application has been made for admission of 57,441,821 new Ordinary Shares to trading on AIM, expected to commence around October 31, 2025, at 8:00 a.m. Following admission, the Company's issued ordinary share capital will comprise 251,072,642 Ordinary Shares, representing the total number of voting rights. Executive Ch</description>
</item>
</channel>
</rss>